Immuneering Co. (NASDAQ:IMRX) Sees Large Decline in Short Interest

Immuneering Co. (NASDAQ:IMRX - Get Free Report) was the recipient of a large decrease in short interest in April. As of April 15th, there was short interest totalling 771,300 shares, a decrease of 27.9% from the March 31st total of 1,070,000 shares. Based on an average daily trading volume, of 215,400 shares, the days-to-cover ratio is currently 3.6 days. Currently, 3.0% of the shares of the stock are short sold.

Hedge Funds Weigh In On Immuneering

A number of institutional investors and hedge funds have recently bought and sold shares of IMRX. HighTower Advisors LLC raised its stake in Immuneering by 33.7% during the 4th quarter. HighTower Advisors LLC now owns 71,360 shares of the company's stock valued at $157,000 after purchasing an additional 18,000 shares during the period. Rockefeller Capital Management L.P. acquired a new stake in Immuneering during the 4th quarter worth about $390,000. XTX Topco Ltd grew its stake in Immuneering by 177.2% during the 4th quarter. XTX Topco Ltd now owns 32,650 shares of the company's stock valued at $72,000 after acquiring an additional 20,871 shares in the last quarter. Two Sigma Investments LP boosted its holdings in shares of Immuneering by 25.0% during the fourth quarter. Two Sigma Investments LP now owns 50,557 shares of the company's stock worth $111,000 after purchasing an additional 10,126 shares during the period. Finally, Tang Capital Management LLC acquired a new position in Immuneering in the 4th quarter valued at approximately $27,000. Institutional investors own 67.65% of the company's stock.

Immuneering Stock Down 3.9 %

Shares of IMRX traded down $0.05 during mid-day trading on Friday, reaching $1.24. 188,762 shares of the stock traded hands, compared to its average volume of 2,339,606. The firm has a market cap of $44.62 million, a price-to-earnings ratio of -0.63 and a beta of -0.25. The stock has a fifty day simple moving average of $1.47 and a 200 day simple moving average of $1.82. Immuneering has a 12-month low of $1.00 and a 12-month high of $3.83.

Immuneering (NASDAQ:IMRX - Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.16). On average, equities research analysts expect that Immuneering will post -1.86 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on IMRX. Needham & Company LLC reissued a "buy" rating and issued a $12.00 target price on shares of Immuneering in a research note on Thursday, April 10th. Chardan Capital restated a "buy" rating and set a $13.00 target price on shares of Immuneering in a research report on Monday, March 24th.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.